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Introduction: Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying
mechanisms are not fully understood. In this study, the metabolomic and transcriptomic characteristics of a large
panel of human breast cancer xenograft models were mapped, with focus on choline metabolism.
Methods: Tumor specimens from 34 patient-derived xenograft models were collected and divided in two. One part
was examined using high-resolution magic angle spinning (HR-MAS) MR spectroscopy while another part was analyzed
using gene expression microarrays. Expression data of genes encoding proteins in the choline metabolism pathway
were analyzed and correlated to the levels of choline (Cho), phosphocholine (PCho) and glycerophosphocholine (GPC)
using Pearson’s correlation analysis. For comparison purposes, metabolic and gene expression data were collected from
human breast tumors belonging to corresponding molecular subgroups.
Results: Most of the xenograft models were classified as basal-like (N = 19) or luminal B (N = 7). These two
subgroups showed significantly different choline metabolic and gene expression profiles. The luminal B xenografts
were characterized by a high PCho/GPC ratio while the basal-like xenografts were characterized by highly variable
PCho/GPC ratio. Also, Cho, PCho and GPC levels were correlated to expression of several genes encoding proteins in
the choline metabolism pathway, including choline kinase alpha (CHKA) and glycerophosphodiester phosphodiesterase
domain containing 5 (GDPD5). These characteristics were similar to those found in human tumor samples.
Conclusion: The higher PCho/GPC ratio found in luminal B compared with most basal-like breast cancer xenograft
models and human tissue samples do not correspond to results observed from in vitro studies. It is likely that
microenvironmental factors play a role in the in vivo regulation of choline metabolism. Cho, PCho and GPC were
correlated to different choline pathway-encoding genes in luminal B compared with basal-like xenografts,
suggesting that regulation of choline metabolism may vary between different breast cancer subgroups. The
concordance between the metabolic and gene expression profiles from xenograft models with breast cancer
tissue samples from patients indicates that these xenografts are representative models of human breast cancer
and represent relevant models to study tumor metabolism in vivo.Introduction
Breast cancer is not a single disease with variable mor-
phologic features, but rather a group of molecularly dis-
tinct neoplastic disorders [1]. According to the gene
expression-based intrinsic classification, breast carcinomas
can be categorized into at least five subtypes: luminal A,
luminal B, normal breast-like, human epidermal growth* Correspondence: mariatg90@hotmail.com
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reproduction in any medium, provided the orfactor receptor 2 (HER2) enriched, and a basal-like sub-
type [2,3]. In addition to the distinctly different gene ex-
pression patterns, the subgroups also show significantly
different clinical outcomes [3], likely to be caused by alter-
ations in specific cellular pathways. Moreover, tumors that
appear to have similar diagnostic features, do not always
respond to treatment in the same way. This can, among
other factors, be caused by differences in mutational pro-
file, signaling redundancy and the particular tumor micro-
environment [4].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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models are established from a limited number of cell lines
isolated from human tumors grown in cell culture before
implantation into immunodeficient animals. These models
do not reflect the breast cancer heterogeneity since they
usually have a monomorphic, poorly differentiated
histology and lack of tissue organization [5]. A panel of
patient-derived xenograft models has been established in
which human breast tumor tissue has been engrafted dir-
ectly into mice [6-8]. Patient-derived xenograft models
generally maintain key features of the original tumors,
including histologic subtype, degree of differentiation,
growth pattern, and gene expression profiles, even after
several passages in vivo [5-10]. Furthermore, the drug re-
sponse in these models shows a good correlation with the
primary patient tumors [5,6,11], and altogether the xeno-
grafts are representative model systems for studies of
metabolic and genetic patterns in human breast cancer.
Abnormal choline metabolism is a well-known feature
of breast cancer. An elevated total choline (tCho) signal
can be observed using magnetic resonance spectroscopy
(MRS) and is an in vivo biomarker for malignant disease
[12]. In line with this, a reduction in tCho has been sug-
gested as an in vivo marker for response to treatment
[13]. High-resolution magic angle spinning (HR-MAS)
MRS has proven to be a useful technique for assessment
of choline (Cho) metabolism, as it allows detection of in-
dividual Cho metabolites in intact tissue specimens.
High levels of Cho and phosphocholine (PCho), which
are the main contributors to the tCho signal, have been
demonstrated in cultured breast cancer cells [14,15],
while high levels of glycerophosphocholine (GPC) have
been detected in human breast cancer biopsies and xe-
nografts [16-18]. Cho metabolism has been shown to be
altered following chemotherapy [19,20], and several en-
zymes involved in Cho metabolism have been identified
as potential drug targets [21,22]. Despite the potential
diagnostic value of Cho-containing compounds, the
underlying mechanisms causing the alterations in Cho
metabolism are not fully understood [23]. Integration of
metabolic abnormalities and altered gene expression
profiles provides new insights into the underlying regu-
latory network. Elucidation of the biochemical mecha-
nisms governing Cho metabolism may be useful in the
development of prognostic and predictive tools in breast
cancer management.
The purpose of this study was to map the metabolo-
mic and transcriptomic characteristics of 34 patient-
derived breast cancer xenografts, with a special focus
on Cho metabolism. In order to evaluate the clinical
relevance of the xenograft models for metabolism stud-
ies, human breast cancer biopsies from the correspond-
ing molecular subtypes were analyzed using identical
methods.Methods
Xenograft models
Patient-derived breast cancer xenograft models (N = 34)
were established at Institute Curie, France (N = 32) or
Institute for Cancer Research, Oslo University Hospital
(N = 2), either from primary tumor tissue (N = 28), axil-
lary lymph node metastases (N = 4) or metastasis from
distant organs (N = 2), as previously described [6-8].
Briefly, primary mammary tumor specimens were im-
planted into immunodeficient mice receiving estrogen-
enriched drinking water. After initial establishment, the
tumor tissue from the xenografts was serially trans-
planted in mice with passage times of two to eight
months. Histopathology and immunohistochemistry data
from the xenografts was obtained as previously de-
scribed [6,24]. Twenty nine xenograft tumors were clas-
sified as invasive ductal carcinomas (IDC), two were
classified as invasive lobular carcinomas (ILC), one as
ductal in situ carcinoma (DCIS), one as invasive cribri-
form carcinoma (ICC) and one as micropapillary carcin-
oma (IMPC). Hormone receptor status of estrogen (ER)
and progesterone (PgR) was determined where samples
with ≥10% staining cancer cells were considered recep-
tor positive [24]. For the HER2, only membranous
staining was interpreted as previously described [25],
and protein positivity was defined if ≥65% of the cells
were positive. The use of all tissue was evaluated and
approved by appropriate ethics research authorities
(Norway: Regional Committee for Medical and Health
Research Ethics (REC), South East, reference number
S-07398a. France: French Ethics Committee, Agree-
ment B75-05-18). Informed written consent was ob-
tained from all but for the two Norwegian patients,
who passed away before this issue was addressed. This
was evaluated and the need for such consent was
waived by the Regional Committee for Medical and
Health Research Ethics, South-East Norway. All experi-
ments were conducted according to the regulations of
the Federation of European Laboratory Animal Science
Association (FELASA).
Tumor tissue was harvested from each of the xenograft
models, immediately frozen in liquid nitrogen and stored
under cryogenic conditions until analysis. Tumor samples
from each model were later divided into two pieces, one for
HR-MAS MRS and one for gene expression analysis.
Human tissue samples
Three different patient cohorts were included in this
study. Human breast cancer biopsies were analyzed
using the same methods as for the xenograft models.
Gene expression data from breast cancer tissue samples
from patients (N = 152) in Cohort 1 (from three different
hospitals in the Oslo region, Norway) were used solely
to mean center global gene expression data from the
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(N = 50, from two different hospitals in the Trondheim
region, Norway) was used to evaluate metabolic charac-
teristics in breast cancer subgroups. The MR spectra
from the breast cancer tissue samples were selected
from our local spectral database based on ER receptor sta-
tus. The samples were previously classified as ER positive
(N = 37) and ER negative (N = 13) measured by immuno-
histochemistry (IHC). The ER staining cut-off point was
10% (that is, <10% considered negative). Breast cancer tis-
sue samples from patients (N = 115) in Cohort 3 (patients
enrolled at The Norwegian Radium Hospital) were used
for comparative analysis of gene expression between
human and xenograft samples. This patient material was
collected and gene expression analysis performed as previ-
ously described in [26,27]. Only basal-like (N = 18) and lu-
minal B samples (N = 14) were selected from the data set,
and only expression of genes directly involved in Cho me-
tabolism was used in the analyses. An overview of the
xenograft samples, patient cohorts and analyses is shown
in Figure 1. The use of all patient materials was approvedFigure 1 Flowchart of xenograft samples, human tissue samples and ex
and tissue samples from three patient cohorts (white rectangles). The experim
by dashed rectangles. ER, estrogen receptor; HER2; human epidermal growthby Regional Committees for Medical and Health Research
Ethics (South East and Central Norway), and informed
written consent was obtained from all included patients.
Breast cancer subclassification using gene expression in
xenograft models
RNA extraction and microarray hybridization of
xenograft tissue
Total RNA from 34 snap frozen xenograft tissue samples
was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. Total
RNA concentration was measured using NanoDrop
(NanoDrop Technologies, Wilmington, DE, USA) and the
quality was evaluated using 2100 Bioanalyzer (Agilent
Technologies, Waldbronn, Germany). A total of 100 to
125 ng RNA was amplified and labeled with cy3-CTP fol-
lowing the Agilent Low Input Quick Amplification Label-
ing Kit protocol for One-Color Microarray-Based Gene
Expression Analysis. Hybridization was performed accord-
ing to the manufacturer’s protocol (Agilent One-Color
Microarray-Based Gene Expression Analysis v6.5) usingperiments. The study includes 34 xenograft models (grey rectangles)
ents performed on the xenografts and human tissue samples are shown
factor receptor 2; ND, not determined; PgR, progesterone receptor.
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Human Gene Expression 8x60K Microarrays. The microar-
rays were scanned using Agilent Technologies Microarray
Scanner (G2505C). Data were extracted from the scanned
images using Feature Extraction software (Agilent Tech-
nologies), version 10.7 and protocol GE1-107-Sep09 for
mRNA. Four xenograft samples (HBCx-11, HBCx-23,
HBCx-29, and HBCx-33) were excluded from further ana-
lyses due to poor data quality.
Processing, normalization, and molecular subtyping
Raw signals were detrended for multiplicative effects using
Agilent’s GenomeAnalyzer and log2 transformed. Data
from control probes were excluded, as well as spots that
were defined as feature outliers from Feature Extraction
due to quality assessment and non-uniform signal distri-
bution. Data were then quantile normalized (R, limma
package) and missing values imputed using LLSimpute
(R, pcaMethods package). The dataset was generated by
additionally averaging the signal intensity of the mul-
tiple unique probes for each gene based on GeneSymbol
as provided by Agilent in the annotation file. This set in-
cluded data for 21,851 unique genes on 30 microarrays
from 30 breast cancer xenografts.
In order to determine the molecular intrinsic subtype
of the xenograft tumors, the gene expression data from
the 30 samples were mean centered against a larger,
more heterogeneous human breast cancer gene expres-
sion dataset of 152 tumors (Cohort 1): for each probe,
the mean expression in the reference dataset was sub-
tracted from the probe signal in each of the xenograft
samples. Probes from the xenograft dataset were
matched to the CloneIDs (CLID) representing the intrin-
sic genes by corresponding GeneSymbol, obtaining Gen-
eSymbols corresponding to each CLID from the Source
tool [28]. For each CLID, if there was more than one
matching probe, their expression values were averaged.
The molecular subclassification of the xenografts was
determined based on distinct variation in gene expression
pattern of 500 ‘intrinsic’ genes, characteristic for five major
molecular breast cancer subtypes. Five expression cen-
troids, calculated for the intrinsic core members of each of
the five subclasses [29] were used to determine correlation
coefficients between the centroids and each of the 30 xe-
nografts, estimating the xenograft molecular subtype by
assigning the subtype which had the highest correlation
coefficient to each of the xenografts. The microarray data
are available at the Gene Expression Omnibus (GEO) with
accession number GSE44666.
HR-MAS MRS analysis
HR-MAS MRS of xenograft tissue
HR-MAS MR spectra from 33 of the xenograft tumor
models were acquired. No tumor tissue was availablefor HR-MAS MRS analysis from one of the models
(HBCx-26). Before running the HR-MAS MRS experi-
ments, 3 μL of phosphate-buffered saline (PBS in D2O)
containing the internal standards trimethylsilyl tetra-
deuteropropionic acid (TSP, 79.86 mM) and formate
(78.80 mM) was added to a disposable insert. The
xenograft samples (9.9 ± 2.6 mg) were cut to fit into the
disposable insert and placed into a zirconium HR-MAS
rotor (4 mm diameter, 80 μL). The HR-MAS MR spec-
tra were acquired using a Bruker Avance III 600 MHz/
54 mm US with a 1H/13C MAS probe with a gradient
aligned with the magic angle axis (Bruker Biospin,
Rheinstetten, Germany). Samples were spun at 5 kHz,
and all experiments were performed at 5°C.
1H MR spectra were obtained using a water presatura-
tion sequence (zgpr; Bruker) and a 90° pulse. Water sup-
pression was achieved by irradiation during recycling
delay (five seconds). Thirty-two Free Induction Decays
(FIDs) were acquired into 32 K points during 3.4 sec-
onds. Total acquisition time was about 4.6 minutes. The
FIDs were multiplied with a 0.3Hz exponential line broad-
ening and Fourier transformed with no zero filling. All
spectra were phased and baseline corrected. Chemical
shifts were calibrated to creatine at 3.04 ppm.
HR-MAS MRS of human tissue
Similarly to the xenograft samples, the MR spectra from
patient Cohort 2 were acquired at 5°C with a spin rate
of 5 kHz. In brief, a 50 μL rotor was filled with buffer
containing D2O, PBS, TSP (1.37 mM), and formate
(10.98 mM). The tissue samples (17.0 ± 4.7 mg) were cut
to fit the rotor. 1H MR spectra were obtained using a water
presaturation sequence (zgpr; Bruker) and a 90° pulse with
a Bruker Avance DRX600 spectrometer equipped with a
1H/13C MAS probe and a gradient aligned with the
magic angle axis (Bruker Biospin). Water suppression
was achieved by irradiation during recycling delay
(three seconds). Thirty-two FIDs were acquired during
2.7 seconds into 32 K and Fourier transformed with no
zero filling. Total acquisition time was about 3.8 minutes.
The spectra were phased and baseline corrected and
chemical shifts were calibrated to creatine at 3.04 ppm.
Quantification of metabolites
Pulse length based concentration determination (PUL-
CON) was used for quantification of Cho, PCho and
GPC in the xenograft tissue samples. PULCON can be
used to measure metabolite concentrations without the
use of an internal reference [30]. For quantification of
the metabolites in the human tissue samples in Cohort
2, metabolite peak areas of Cho, PCho and GPC were re-
lated to the internal standard TSP and sample wet
weight. The areas under the Cho, PCho and GPC peaks
were determined by curve fitting (PeakFit v 4, Systat
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Lorentzian line-shapes (Voigt function). Two-sample t-
tests were performed to assess differences in the metabol-
ite concentrations and ratios between the breast cancer
subgroups. The level of significance was set at P <0.05.
Multivariate statistical analysis of MR spectra
For multivariate analysis, the MR spectra from the xeno-
graft samples were converted to ASCII-files, baseline
corrected [31] and peak aligned [32]. The spectral area
from 3.0 to 4.7 ppm was selected for multivariate ana-
lysis. Regions in the spectra with high signals from fatty
acids, water and ethanol contaminations were excluded.
The MR spectra were normalized and mean centered
prior to analysis. Principal component analysis (PCA)
was performed (PLS toolbox, Matlab) to visualize the
spectral characteristics and to compare the metabolic
differences between samples.
Statistical analysis of gene expression profiles
A total of 55 genes coding for proteins assumed to be
directly associated with Cho metabolism were selected.
The selection criteria were: 1) a selection of genes in-
volved in the KEGG Homo sapiens glycerophospholipid
pathway hsa:00564 which have a possible catalytic specifi-
city in this pathway [33]; and 2) genes coding for proteins
reported to be involved in Cho transport [34], or 3) in-
volved in degradation of GPC [35]. One gene (PLA2G4B)
was excluded because it was not found in the gene array.
PCA (PLS toolbox, Matlab) was performed on the gene
expression data from the 54 selected Cho genes to com-
pare gene expression characteristics between the xenograft
samples. The gene data were mean normalized and mean
centered prior to analysis.
Correlation analysis between choline metabolites and
genes in xenografts
In order to identify genes directly associated with regula-
tion of Cho metabolism, the correlation between the 54
selected Cho genes and the concentrations of three metab-
olites, Cho, PCho and GPC was calculated using Pearson’s
correlation test. This analysis was repeated separately for
the basal-like and luminal B subgroups, in order to evalu-
ate differences in regulation of Cho metabolism between
these subtypes.
Correlation analysis between choline genes in xenografts
and human tissue
In order to assess if the panel of xenograft models was
representative for human disease, the average difference
in expression of the 54 Cho-related genes between
basal-like and luminal B subtype samples was computed.
One gene (ASPG) was excluded because it was not
found in the gene array from the patient tissue samples.Fifty three of the genes were present in the dataset both
for the patient samples (Cohort 3) and the xenografts. In
order to validate the relevance of the xenograft models,
a Pearson correlation test was performed between genes
from the patient and the xenograft subtypes. For all
these analyses, the level of statistical significance was de-
fined at fdr <0.1.
Results
The majority of xenograft tumors were classified as basal-
like and luminal B subtypes
The expression of ER, PgR and HER2 receptors of the 34
xenograft models was previously determined by IHC and
real-time quantitative reverse transcription-PCR (RT-PCR)
methods [6,7,24]. In order to further characterize these
models, the gene expression analysis was carried out
with the Agilent microarray platform. Nineteen samples
were classified as basal-like, one as luminal A, seven as
luminal B, and three samples as HER2 enriched. Five out
of seven luminal B tumors had positive ER status, while all
basal-like tumors were classified as ER negative. Two of
the three HER2 enriched tumors were characterized by
positive HER2 membrane staining. A detailed description
of each xenograft models is given in Table 1.
Metabolic characterization
PCho/GPC ratio in subtypes of breast cancer
Mean MR spectra from the basal-like (N = 19) and lu-
minal B (N = 6) xenograft samples are shown in Figure 2a
and 2b, respectively. The luminal-like samples were char-
acterized by a high PCho/GPC ratio (2.5 ± 0.9), and only
one sample with GPC > PCho. The basal-like samples
were characterized with a higher variation in the PCho/
GPC ratio (1.6 ± 1.2) and the majority of the samples with
GPC > PCho were present in this group (8 of 19 MR
spectra). Figure 2c and 2d show mean MR spectra of
xenograft samples from ER negative (N = 27) and ER
positive (N = 6) xenograft samples. Mean MR spectra
from the ER negative (N = 13), and ER positive (N = 37)
samples from patient Cohort 2 are shown in Figure 2e and
2f, respectively. A higher PCho/GPC level was observed in
the ER positive (2.0 ± 1.1) compared to the ER negative
(1.0 ± 0.7) human tissue samples (P < 0.01). PCho/GPC box
plots for the different subgroups are shown in Additional
file 1. In one MR spectrum from the xenografts, and two
MR spectra from patients, the measured PCho/GPC ratios
were excluded since they were classified as outliers by the
extreme studentized deviate analysis (P < 0.05) [36]. All
outliers had a high PCho/GPC ratio.
Multivariate analysis reveals metabolic differences between
subtypes of breast cancer
PCA was performed on the MR spectra from the xeno-
grafts to investigate the metabolic characteristics of the
Table 1 Molecular characteristics of the 34 xenografts
Intrinsic molecular subtype Receptor status Histological classification Metastasis
Model Basal-
like
Luminal
B
Luminal
A
HER2
enriched
Unknown ER
pos.
PgR
pos.
HER2
pos.
IDC ILC ICC DCIS IMPC Node Distant
HBCx-1 X X
HBCx-4B X X X
HBCx-7 X X X
HBCx-8 X X
HBCx-9 X X
HBCx-10 X X
HBCx-12A X X
HBCx-12B X X X
HBCx-14 X X
HBCx-15 X X
HBCx-16 X X
HBCx-17 X X
HBCx-24 X X
HBCx-27 X X
HBCx-28 X X
HBCx-30 X X
HBCx-39 X X
HBCx-41 X X X
MAS98.12 X X
HBCx-3 X X X
HBCx-5 X X X X X
HBCx-19 X X X
HBCx-26 X X X X
HBCx-31 X X
HBCx-34 X X X X
MAS98.06 X X X X
HBCx-21 X X X X
HBCx-13A X X X
HBCx-13B X X X X
HBCx-40 X X
HBCx-11 X X
HBCx-23 X X
HBCx-29 X X X X X
HBCx-33 X X
Total
numbers
19 7 1 3 4 7 4 6 29 2 1 1 1 4 2
The table reports on intrinsic molecular subtype, receptor status, histological classification and metastatic potential.
DCIS, ductal in citu carcinoma; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ICC, invasive cribriform carcinoma; IDC, invasive ductal
carcinoma; ILC, invasive lobular carcinoma; IMPC, invasive micropapillary carcinoma; PgR, progesterone receptor
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and loading plot). Most of the luminal B samples are
clustered in the top left corner of the score plot with a
low principal component 2 (PC2) score and a high PC3
score. Samples with low PC2 scores are characterized byhigher levels of PCho, creatine, taurine, glycine and lac-
tate, and lower levels of GPC and Cho, compared to
samples with a high PC2 score. PC2 accounted for 20%
of the variance between the samples, and the loading
profile indicates a large contribution from the amount of
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Figure 2 Mean MR spectra of different breast cancer subtypes. MR spectra of a) basal-like (N = 19), b) luminal-B (N = 6), c) ER negative
(N = 27) and d) ER positive (N = 6) xenograft samples, and of e) ER negative (N = 13), and f) ER positive (N = 37) breast cancer tissue samples
from patients. Abbreviations: Lac: lactate, PE: phosphoethanolamine, Cre: creatine, Gln: glutamine, Glu: glutamate, Gly: glycine, Tau: taurine,
GPC: glycerophosphocholine, PCho: phosphocholine, Cho: choline.
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http://breast-cancer-research.com/content/16/1/R5PCho and GPC. PC3 explained 8% of the variance be-
tween the samples. Samples with high PC3 scores are
characterized with higher levels of glycine, taurine, GPC,
Cho and creatine, and lower levels of lactate and PCho.PC1 showed that the largest variance between the sam-
ples (43%) was caused by variations in lipid content (data
not shown). No clustering of breast cancer subgroups
was found in PC1.
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Figure 3 Score plot and loading profiles (dotted arrows) from PCA of HR-MAS MR spectra and expression of genes encoding proteins
in the choline pathway in the xenograft tissue samples. a) Bi-plot of PC2 and PC3 from HR-MAS MR spectra (N = 33). b) Bi-plot of PC1
and PC2 for selected genes contributing to choline metabolism. HR-MAS MR, high resolution magic angle spinning magnetic resonance; PCA,
principal component analysis.
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human tissue samples
Multivariate analysis reveals differences in gene expression
of genes involved in choline metabolism between subtypes
of breast cancer
In order to map the gene expression characteristics of
the Cho metabolism pathway in the xenograft models, a
PCA was performed. Figure 3b shows the bi-plot from
PCA based on the expression data of the 54 genes in the
Cho pathway. Most of the luminal B samples are clus-
tered in the bottom left corner of the score plot with a
low PC1 and a low PC2 score. These samples are char-
acterized with a high expression of glycerol-3-phosphate
dehydrogenase 1-like (GPD1L), phospholipase C, delta 4
(PLCD4) and glycerophosphodiester phosphodiesterase
domain containing 3 (GDPD3). Most of the basal-like
samples are clustered to the right of the score plot with
a high PC1 score. These samples are characterized with
high expression of phospholipase C, gamma 2 (PLCG2),
phospholipase domain containing 3 (PNPLA3), phospho-
lipase C, epsilon 1 (PLCE1) and phospholipase A2, group
IVA (PLA2G4A).
Correlations between choline metabolites and gene
expressions in xenograft models
To detect associations between the expression of Cho
genes and the concentrations of Cho, PCho and GPC, acorrelation analysis was performed. Across all xenograft
models, ten of the 54 genes contributing to Cho metab-
olism were found to be correlated with Cho, PCho or
GPC concentration (P <0.05), as shown in Table 2 and
Figure 4a. Cho was positively correlated with the expres-
sion of CHPT1, phospholipase A2, group IB (PLA2G1B)
and patatin-like phospholipase domain containing 6
(PNPLA6). PCho was positively correlated with expres-
sion of choline kinase α (CHKA) and glycerophospho-
diester phosphodiesterase domain containing 5 (GDPD5).
GPC was positively correlated with CHKA, GDPD5, phos-
pholipase A2 group VI (PLA2G6), phospholipase C, delta
1 (PLCD1) and patatin-like phospholipase domain con-
taining 7 (PNPLA7), and negatively correlated with
lysophospholipase 1 (LYPLA1) and phospholipase D
family, member 3 (PLD3). In addition, a high expres-
sion of CHKA was also found to be correlated with high
expression of GDPD5, and PCho concentration was posi-
tively correlated to GPC concentration. Scatter plots of
correlations between metabolites and gene expressions are
shown in Figure 4c-4f.
Correlation between choline metabolites and gene
expression within the basal-like and luminal B subgroups
The correlation analysis was then performed separately
for basal-like and luminal B xenograft samples, in order
to identify potential differences in regulation of Cho
Table 2 Correlation coefficients (ρ) and levels of
significance (P) between concentration of Cho, PCho, and
GPC, and expression of genes contributing in the choline
metabolism pathway
Subgroup Metabolite Gene ρ P-value
All samples (N = 30) Cho CHPT1 0.49 0.008
PLA2G1B 0.43 0.021
PNPLA6 0.41 0.028
PCho CHKA 0.43 0.021
GDPD5 0.38 0.041
GPC CHKA 0.44 0.017
GDPD5 0.56 0.002
LYPLA1 −0.40 0.030
PLA2G6 0.43 0.021
PLCD1 0.37 0.045
PLD3 −0.42 0.024
PNPLA7 0.39 0.035
Basal-like (N = 19) Cho CHKA 0.46 0.049
CHPT1 0.50 0.029
PLA2G10 0.53 0.021
PLA2G6 0.61 0.006
PCho CHKA 0.47 0.044
PLA2G2E −0.52 0.024
PLCB4 0.51 0.027
GPC CHKA 0.52 0.023
GDPD5 0.73 <0.001
PCYT1B 0.49 0.035
PLA2G6 0.67 0.002
PNPLA7 0.52 0.021
Luminal B (N = 6) Cho CHKB −0.96 0.002
PLA2G12B −0.91 0.012
PLA2G4A 0.86 0.029
PLCD3 −0.86 0.027
PCho PLCB1 −0.91 0.011
PLD1 0.89 0.017
GPC CHKB −0.97 0.001
PLCD3 −0.81 0.049
SLC22A2 −0.86 0.030
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http://breast-cancer-research.com/content/16/1/R5metabolism between these subtypes. When considering
only the basal-like xenograft samples, nine genes were
found to be correlated to either Cho, PCho or GPC, as
shown in Figure 4b) and Table 2. Cho was positively
correlated with CHKA, CHPT1, phospholipase A2,
group X (PLA2G10) and PLA2G6. PCho was positively
correlated with phospholipase C, beta 4 (PLCB4) and
CHKA, and negatively correlated with PLA2G2E. GPCwas positively correlated with CHKA, GDPD5, phosphate
cytidylyltransferase 1, Cho, beta (PCYT1B), PLA2G6 and
PNPLA7. In the luminal B subgroup, Cho, PCho and GPC
were correlated with seven Cho genes. Cho was positively
correlated with PLA2G4A, and negatively correlated with
choline kinase beta (CHKB), phospholipase A2, group
XIIB (PLA2G12B) and phospholipase C, delta 3 (PLCD3).
PCho was found to be positively correlated with phospho-
lipase C, delta 1 (PLD1), and negatively correlated with
phospholipase C, beta 1 (PLCB1), while GPC was found to
be negatively correlated with solute carrier family 22,
member 2 (SLC22A2), CHKB and PLCD3. A list of all cor-
relations between Cho, PCho, and GPC versus Cho genes
is shown in Additional file 2.
Correlations between choline genes in xenografts and
human tissue
The differential expression of Cho genes between the
basal-like and luminal B subtypes was studied both in
xenograft and human tissue samples. A strong correl-
ation (ρ = 0.79, P <1.3e-12) was observed when expres-
sion of genes in the Cho metabolism pathway was
compared in tissue samples from xenografts and breast
cancer patients (Cohort 3). Figure 5 shows differences in
gene expression between basal-like and luminal B sam-
ples for xenografts and human tissue samples. The plot
demonstrates that six genes: PLCG2, PLCE1, PLA2G4A,
PNPLA3, PLCD1 and lecithin-cholesterol acyltransferase
(LCAT), were significantly higher expressed in basal-like
compared to luminal B samples, both for the xenografts
and human tissue samples. Five genes: PLCD4, GPD1L,
GDPD3, phospholipase A2, group XIIA (PLA2G12A)
and LYPLA1, were significantly lower expressed in
basal-like compared to luminal B samples, for both the
xenografts and human tissue samples. A list of all gene
expressions, differences in gene expressions between
basal-like and luminal B tissue samples, P-values and
fdr-values for the patients and the xenograft samples is
given in Additional file 3.
Discussion
In this study, metabolic and gene expression profiles of
34 patient-derived breast cancer xenograft models have
been characterized and compared with patient breast
cancer samples. The majority of the xenograft models
was classified as basal-like and had a triple-negative re-
ceptor status. The gene expression profiling was consist-
ent with IHC assessments previously reported for these
tumors [7,24]. The luminal B/ER positive xenograft sam-
ples were characterized by a high PCho/GPC ratio. For
the basal-like subgroup, a larger variation in the PCho/
GPC ratio was found within the xenograft samples. The
metabolic profiles of the xenografts corresponded well
with the profiles obtained from human breast cancer
a)
b)
c) d)
e) f)
Figure 4 (See legend on next page.)
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Figure 4 Major metabolites and genes contributing to the choline metabolism pathway. a) Genes (oval) in choline metabolism being
either positively (arrows upwards) or negatively (arrows downward) correlated with Cho, PCho or GPC (rectangles) in the xenograft models. High
expressions of CHPT1, PLA2G1B and PNPLA6 (marked with dots and solid outlines) are associated with high levels of Cho. High expressions of
CHKA and GDPD5 (black outlines) are associated with high levels of PCho. High expressions of CHKA, GDPD5, PLA2G6, PLCD1 and PNPLA7, and low
expressions of LYPLA1, and PLD3 (dashed outlines) are associated with high levels of GPC. b) Genes (oval) that are either positively or negatively
correlated with Cho, PCho or GPC (rectangles) in the basal-like, and luminal B subgroup. In the basal-like subgroup (red), high expressions of
CHKA, CHPT1, PLA2G10 and PLA2G6 (dots and solid outlines) are associated with high levels of Cho. High expressions of CHKA and PCLB4, and a
low expression of PLA2G2E (solid outlines) are associated with high levels of PCho. High expressions of CHKA, GDPD5, PCYT1B, PLA2G6 and PNPLA7
(dashed outlines) are associated with high levels of GPC. In the luminal B subgroup (cyan) a high expression of PLA2G4A, and low expressions of
CHKB, PLA2G12A and PLCD3 (dots and solid outlines) are associated with high levels of Cho. A high expression of PLD1, and a low expression of
PLCB1 (solid outlines), are associated with high levels of PCho. In addition, low levels of CHKB, PLCD3 and SLC22A2 (dashed outlines) are associated
with high GPC levels. c-f) Scatter plots of correlation between c) PCho and CHKA, d) GPC and GDPD5, e) PCho and GPC and f) GDPD5 and CHKA.
ρ: Pearson’s correlation coefficient, Gene expression: normalized log 2 transformed.
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tabolism was found to be different in luminal B and
basal-like xenograft models, which also were in accord-
ance with findings in the corresponding subgroups of
human breast tumor tissue samples.Significant at fdr<0.1
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Figure 5 Comparison of choline gene expressions between basal-like
Blue dots show genes being differentially expressed for basal-like versus lu
show genes being differentially expressed for basal-like versus luminal B fo
expressed for basal-like versus luminal B subgroups for the human tissue sa
between basal-like and luminal B samples in neither the xenografts nor theEighteen of twenty four triple-negative samples were
classified as basal-like cancers. These results corre-
sponded well with findings from other studies, since ap-
proximately 90% of triple-negative breast carcinomas are
classified as basal-like [29,37]. In addition, expression ofpression basal-like – luminal B
and luminal B xenografts and human tissue samples (Cohort 3).
minal B, both for the xenografts and human tissue samples. Green dots
r the xenograft models only, while red dots show genes differentially
mples only. Black dots are genes not being differentially expressed
human tissue samples.
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subtypes of breast cancer [38], and all of the ER positive
xenografts were found to be luminal A or B. Overall, the
association between histopathological characteristics and
intrinsic molecular subclassification was in accordance
with previously published data [39]. This confirms that
the molecular subclassification of xenografts reflects the
typical characteristics seen in human disease despite the
presence of mouse stromal cells and thereby potentially
different tumor/host interaction than in human tumors.
In concordance with the high PCho/GPC ratio in the
luminal-like/ER positive xenografts, significantly higher
PCho/GPC levels were found in the ER positive versus
ER negative samples from breast cancer patients. These
results are in agreement with findings in other studies of
human breast cancer tissue and xenografts [17,40] but
do not correspond to results from in vitro studies. Stud-
ies of a panel of cultured cell lines have suggested that
malignancy is associated with high PCho and low GPC
levels [14]. High GPC levels found in vivo, both in xeno-
graft tissue and clinical samples, suggests that this hy-
pothesis has to be refined. Due to the discrepancy
between in vitro and in vivo data, it is tempting to
speculate that microenvironmental factors may play a
role in the in vivo regulation of Cho metabolism [41,42].
In addition, there is a possibility that high GPC concen-
trations could be linked to differences in driver muta-
tions between ER positive and ER negative tumors.
Luminal-like breast cancer is strongly associated with ER
expression, and metabolism is likely tightly regulated by
ER-mediated mechanisms. In basal-like breast cancer,
the impact of ER (and HER2) –mediated signaling plays
a smaller role. The activity in other signaling pathways,
such as PI3K and MAPK, is, therefore, comparatively
more important, resulting in a more heterogeneous
metabolic profile.
The results from the gene expression profiles indicated
that the genes involved in Cho metabolism were differ-
entially expressed in luminal B compared to basal-like
xenograft samples. The luminal B xenograft samples
were found to have a higher expression of PLCD4,
GDPD3 and GPD1L, while the basal-like samples were
characterized with higher expression of PLCG2, PNPLA3
and PLCE1. In addition, the concentrations of Cho,
PCho and GPC were correlated with the expression of
different genes in different breast cancer subgroups. This
suggests that luminal B and basal-like breast cancer may
have different mechanisms regulating Cho metabolism.
The concordance between the gene expression profiles
from the xenograft models and breast cancer tissue sam-
ples confirmed the assumption that these xenografts are
representative models of human breast cancer.
Although tCho is proposed as an in vivo biomarker in
breast cancer, the regulation of Cho metabolism is notfully understood. The current consensus is that the
transport of Cho into cancer cells is increased com-
pared to normal cells. In vitro, increased expression of
various Cho transporter proteins has been demon-
strated, and in vivo PET studies using [11C]-choline or
[18 F]-fluorocholine have indicated increased uptake of
Cho both in preclinical models and clinical studies
[43-46]. Furthermore, it has been shown that CHKA is
upregulated in several cancers, and that CHKA expres-
sion correlates with PCho concentration in vitro
[45,47]. In our study, the positive correlation between
CHKA expression and PCho concentration in xenograft
tumors was confirmed. The regulation of GPC is poorly
understood [48], which is a challenge as this metabolite
contributes significantly to the tCho signal measured by
in vivo MRS. Several studies have demonstrated that
GPC may be a potential biomarker for response to
treatment [21,49-52], and it is, therefore, necessary to
elucidate the mechanisms responsible for regulating
GPC concentration in vivo. We found a positive correl-
ation between CHKA and GPC concentration, which is
not surprising as PCho and GPC concentrations are posi-
tively correlated. This suggests that malignant transform-
ation and upregulation of CHKA leads to a general
increase in PtdCho turnover, which is reflected by a high
concentration of both precursor (PCho) and degradation
products (GPC) of this cell membrane component. A
positive correlation between GDPD5 and PCho concen-
tration was also found which is in accordance with previ-
ous studies suggesting that GDPD5 may be upregulated in
ER negative breast cancer [53]. As GDPD5 has been sug-
gested to catalyze GPC degradation, the positive correl-
ation between GDPD5 and GPC concentration was not
anticipated. These results suggest that GDPD5 may be a
general marker for abnormal Cho metabolism, but not ne-
cessarily regulating GPC concentration. This interpret-
ation is further supported by the positive correlation
between expression of CHKA and GDPD5.
Various phospholipase enzymes are involved in deg-
radation of PtdCho to GPC, PCho, and Cho but the
roles of the various isoforms are still not fully elucidated.
Several phospholipases are upregulated in cancer com-
pared to normal tissue [54-57], but their impact on the
concentration of Cho-containing metabolites is poorly
understood [58]. The results of this study indicate that
expression of phospholipases varies significantly between
the xenograft models within the different breast cancer
subgroups. However, the large number of phospholipase
isoforms and their complex biology makes it difficult to
interpret the significance of these differences. Numerous
studies have demonstrated complex and often reciprocal
interactions between oncogenic signaling pathways and
enzymes involved in Cho metabolism [23]. Several en-
zymes involved in Cho metabolism, including CHK,
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RAS-mediated signaling [59,60]. MYC and HIF1 have
also been shown to be involved in the regulation of
CHKA [61]. When we observe differences in the Cho
metabolic and gene expression profiles between cancer
subtypes, it may be caused by specific oncogenic signal-
ing pathways that are more frequently upregulated in
some subtypes.
More than 10 years after the first report on molecular
fingerprints in breast cancer [2], there are still active dis-
cussions on the optimal strategy for subtyping breast
cancer. Several research groups advocate an integrated
approach, where data from several –omics platforms are
combined for identification of clinically relevant sub-
types [62,63]. Since MR metabolomics reflect tumor
microenvironment to a larger degree than other –omics
techniques, it can contribute to improved understanding
of the underlying biology in different breast cancer sub-
types. Including metabolic profiles in the criteria for
novel breast cancer subtypes may, therefore, bring us
closer to personalized breast cancer treatment.
In this study, gene expression profiling and metabolo-
mic analysis of 34 patient-derived xenograft models
demonstrated significant difference between luminal B
and basal-like breast cancer. Similar patterns both in
metabolic profiles and expression of Cho genes were
found in the xenograft models and human breast cancer
with corresponding molecular subtype. This panel of
patient-derived xenograft models, therefore, represents a
unique and valuable tool for studies of molecular proper-
ties associated with sensitivity or resistance to chemother-
apy or targeted anticancer drugs. It also allows further
studies of the unique biology of the different subtypes of
breast cancer, which may be important for future clinical
applications based on molecular fingerprints.
Conclusion
HR-MAS MRS and gene expression analyses demon-
strated that the amount of Cho, PCho and GPC corre-
lated with the expression of several genes, including
CHKA and GDPD5, in the Cho metabolism pathway in
tissue samples from patient-derived breast cancer xeno-
grafts representing luminal-like, basal-like and HER2
enriched breast cancer. High PCho/GPC ratios were ob-
served for the luminal-like samples, while a larger vari-
ation in the PCho/GPC ratios was observed for the
basal-like samples. These results corresponded well with
the Cho profiles of human breast cancer samples where
a significantly higher PCho/GPC level was found in ER
positive compared to ER negative cancers. Both the Cho
metabolic profiles and the expression of genes involved
in the Cho metabolism pathway differed between lu-
minal B and basal-like xenografts. Similar differences
were found in human breast cancer samples, and thedifferential gene expression between basal-like and lu-
minal B subtypes was correlated strongly in xenografts
and human samples. The amount of Cho, PCho and
GPC was also correlated to the expression of different
Cho genes in the luminal B compared to the basal-like
subgroup. Differences in the Cho metabolic and gene ex-
pression profiles between cancer subtypes can be caused
by specific oncogenic signaling pathways that are more
frequently upregulated in some subtypes. The findings in
this study indicate that the panel of patient-derived xe-
nografts is representative of human breast cancer, and
may be valuable for further exploration of subtype-
specific metabolic and transcriptomic traits. In addition,
the models are relevant for studies of targeted anticancer
drugs and molecular properties associated with sensitiv-
ity and resistance to chemotherapy.
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and expressions of genes contributing in choline metabolism for the
basal-like tissue samples (N = 19). All genes and metabolites having a
significant correlation (P <0.05) are emphasized in bold. Table S3.
Correlation coefficients and P-values between Cho, PCho, and GPC
concentrations, and expressions of genes contributing in choline
metabolism for the luminal B tissue samples (N = 6). All genes and
metabolites having a significant correlation (P <0.05) are emphasized
in bold.
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Abbreviations
CHKA: choline kinase alpha; CHKB: choline kinase beta; Cho: choline;
CHPT1: choline phosphotransferase 1; Cre: creatine; DCIS: ductal in situ
carcinoma; ER: estrogen receptor; FID: Free Induction Decay;
GDPD3: glycerophosphodiester phosphodiesterase domain containing 3;
GDPD5: glycerophosphodiester phosphodiesterase domain containing 5;
Gln: glutamine; Glu: glutamate; Gly: glycine; GPC: glycerophosphocholine;
GPD1L: glycerol-3-phosphate dehydrogenase 1-like; HER2: human epidermal
growth factor receptor 2; HR-MAS MRS: high resolution magic angle
spinning magnetic resonance spectroscopy; ICC: invasive cribriform
carcinoma; IDC: invasive ductal carcinomas; IHC: immunohistochemistry;
ILC: invasive lobular carcinomas; IMPC: micropapillary carcinoma; Lac: lactate;
LCAT: lecithin-cholesterol acyltransferase; LYPLA1: lysophospholipase 1;
PBS: phosphate-buffered saline; PC1,2,3: principal component 1,2,3;
PCA: principal component analysis; PCho: phosphocholine;
PCYT1B: phosphate cytidylyltransferase 1, choline, beta;
PE: phosphoethanolamine; PgR: progesterone receptor;
PLA2G10: phospholipase A2, group X; PLA2G12A: phospholipase A2, group
XIIA; PLA2G12B: phospholipase A2, group XIIB; PLA2G1B: phospholipase A2,
group IB; PLA2G2E: phospholipase A2, group IIE; PLA2G4A: phospholipase A2,
group IVA; PLA2G6: phospholipase A2, group VI; PLCB1: phospholipase C, beta
1; PLCB4: phospholipase C, beta 4; PLCD1: phospholipase C, delta 1;
PLCD3: phospholipase C, delta 3; PLCD4: phospholipase C, delta 4;
Grinde et al. Breast Cancer Research 2014, 16:R5 Page 14 of 15
http://breast-cancer-research.com/content/16/1/R5PLCE1: phospholipase C, epsilon 1; PLCG2: phospholipase C, gamma 2;
PLD1: phospholipase C, delta 1; PLD3: phospholipase D family, member 3;
PNPLA3: patatin-like phospholipase domain-containing protein 3;
PNPLA6: patatin-like phospholipase domain containing 6; PNPLA7: patatin-like
phospholipase domain containing 7; SLC22A2: solute carrier family 22,
member 2; Tau: taurine; TSP: trimethylsilyl tetradeuteropropionic acid.
Competing interests
The authors declared they have no competing interests.
Authors’ contributions
MTG was involved in the study design, acquired and analyzed the HR-MAS
MRS data and drafted the manuscript. NS performed the gene expression
analysis, interpreted the microarray data and was involved in drafting of the
manuscript. SAM was involved in the study design and in drafting of the
manuscript. EAR performed statistical analyses and interpreted the data. EB
performed gene expression analysis and interpreted microarray data. AK co-
ordinated the xenograft samples. BS was involved in the HR-MAS MRS proto-
col and supervised the analyses. TFB was involved in the study design and in
statistical analyses. ALBD contributed with expertise in molecular biology
techniques. GMM and OE were involved in the coordination of xenografts.
TS was involved the study design and in the interpretation of the microarray
data. EM was responsible for the establishment of the xenograft models and
delivery of samples. ISG designed and coordinated the study. All authors crit-
ically revised, read and approved the final manuscript.
Acknowledgements
The HR-MAS MRS experiments were performed at the MR Core Facility,
Norwegian University of Science and Technology (NTNU). The authors would
like to thank Institute Curie for providing xenograft tissue samples and
Dr. Kristin Andersen for her input in discussion of the gene expression data. This
study was supported by the Liaison Committee between the Central Norway
Regional Health Authority (RHA) and the Norwegian University of Science and
Technology (NTNU), (grant 46021700), South-Eastern Norway Regional Health
Authority (2011042, and 2011097), the Norwegian Cancer Society (2209251,
PR-2006-0272, and 138296 - PR-2008-0108), and the national Functional
Genomics Program (FUGE) of the Research Council of Norway (183621/S10).
Author details
1Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway.
2St. Olavs University Hospital, Trondheim, Norway. 3Department of Tumor
Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.
4Department of Genetics, Institute for Cancer Research, Oslo University
Hospital, Norwegian Radium Hospital, Oslo, Norway. 5Institute of Clinical
Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 6Center for
Cancer Biomedicine & Department of Informatics, University of Oslo, Oslo,
Norway. 7K.G. Jebsen Center for breast cancer research, Institute of Clinical
Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 8Department
of Technology, Sør-Trøndelag University College, Trondheim, Norway.
9Department of Pharmacy, Faculty of Health Sciences, University of Tromsø,
Tromsø, Norway. 10Cancer Stem Cell Innovation Center, Oslo University
Hospital, Norwegian Radium Hospital, Oslo, Norway. 11Department of
Oncology, Oslo University Hospital, Oslo, Norway. 12Preclinical Investigation
Unit, Translational Research Department, Institut Curie, Paris, France.
Received: 8 February 2013 Accepted: 10 January 2014
Published: 21 January 2014
References
1. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic: when
will molecular signatures become relevant to patient care? Nat Rev
Cancer 2007, 7:545–553.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406:747–752.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen
MB, de RM V, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein
D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast
carcinomas distinguish tumor subclasses with clinical implications. Proc
Natl Acad Sci USA 2001, 98:10869–10874.4. Li SX, Sjolund A, Harris L, Sweasy JB: DNA repair and personalized breast
cancer therapy. Environ Mol Mutagen 2010, 51:897–908.
5. Fiebig HH, Burger AM: Human tumor xenografts and explants. In Tumor
Models in Cancer Research. Edited by Teicher BA. Totowa: Humana Press Inc;
2002:167–193.
6. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de
Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M,
Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V,
Poupon MF: A new model of patient tumor-derived breast cancer
xenografts for preclinical assays. Clin Cancer Res 2007, 13:3989–3998.
7. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L,
Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A,
Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E: Molecular
profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012,
14:R11.
8. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, Russnes
HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten
O: Molecular profiling and characterization of luminal-like and basal-like
in vivo breast cancer xenograft models. Mol Oncol 2009, 3:469–482.
9. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R,
Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm
BE, Welm AL: Tumor grafts derived from women with breast cancer
authentically reflect tumor pathology, growth, metastasis and disease
outcomes. Nat Med 2011, 17:1514–1520.
10. Kelland LR: “Of mice and men”: values and liabilities of the athymic nude
mouse model in anticancer drug development. Eur J Cancer 2004, 40:827–836.
11. Jin K, Teng L, Shen Y, He K, Xu Z, Li G: Patient-derived human tumour
tissue xenografts in immunodeficient mice: a systematic review.
Clin Transl Oncol 2010, 12:473–480.
12. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F: In vivo
proton MR spectroscopy of the breast using the total choline peak integral
as a marker of malignancy. AJR Am J Roentgenol 2009, 192:1608–1617.
13. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava
A, Rath GK: Evaluation of total choline from in-vivo volume localized proton
MR spectroscopy and its response to neoadjuvant chemotherapy in locally
advanced breast cancer. Br J Cancer 2001, 84:1016–1022.
14. Aboagye EO, Bhujwalla ZM: Malignant transformation alters membrane
choline phospholipid metabolism of human mammary epithelial cells.
Cancer Res 1999, 59:80–84.
15. Singer S, Souza K, Thilly WG: Pyruvate utilization, phosphocholine and
adenosine triphosphate (ATP) are markers of human breast tumor
progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spec-
troscopy study. Cancer Res 1995, 55:5140–5145.
16. Eliyahu G, Maril N, Margalit RH: Choline Metabolism in breast cancer; the
influence of the microenvironmental conditions: [abstract]. Proc Intl Soc
Mag Reson Med 2007, 2007:15.
17. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE,
Dahl S, Gribbestad IS, Bathen TF: Multivariate modeling and prediction of
breast cancer prognostic factors using MR metabolomics. J Proteome Res
2010, 9:972–979.
18. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS:
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue
with clinical parameters. NMR Biomed 2006, 19:30–40.
19. Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren
S, Gribbestad IS: Assessment of early docetaxel response in an
experimental model of human breast cancer using DCE-MRI, ex vivo HR
MAS, and in vivo1H MRS. NMR Biomed 2010, 23:56–65.
20. Glunde K, Jie C, Bhujwalla ZM: Mechanisms of indomethacin-induced
alterations in the choline phospholipid metabolism of breast cancer
cells. Neoplasia 2006, 8:758–771.
21. Cao MD, Sitter B, Bathen TF, Bofin A, Lønning PE, Lundgren S, Gribbestad IS:
Predicting long-term survival and treatment response in breast cancer
patients receiving neoadjuvant chemotherapy by MR metabolic
profiling. NMR Biomed 2011, 25:269–278.
22. Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal
JC, Ramírez De Molina A: Choline kinase is a novel oncogene that
potentiates RhoA-induced carcinogenesis. Cancer Res 2005, 65:5647–5653.
23. Glunde K, Bhujwalla ZM, Ronen SM: Choline metabolism in malignant
transformation. Nat Rev Cancer 2011, 11:835–848.
24. Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A,
Guyader C, de Plater L, Elbaz C, Karboul N, Fontaine J, Chateau-Joubert S,
Grinde et al. Breast Cancer Research 2014, 16:R5 Page 15 of 15
http://breast-cancer-research.com/content/16/1/R5Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin
D: Modeling of response to endocrine therapy in a panel of human luminal
breast cancer xenografts. Breast Cancer Res Treat 2012, 133:595–606.
25. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche
M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux
I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V: Calibration of immunohis-
tochemistry for assessment of HER2 in breast cancer: results of the
French Multicentre GEFPICS Study. Histopathology 2003, 42:337–347.
26. Navon R, Rødland E, Enerly E, Steinfeld I, Kleivi K, Leivonen S, Aure M,
Russnes H, Rønneberg JH, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume
B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL:
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary
breast tumors. PLoS One 2011, 22:e16915.
27. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjærde OC,
Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM,
Børresen-Dale AL, Sørlie T: Presence of bone marrow micrometastasis is
associated with different recurrence risk within molecular subtypes of
breast cancer. Mol Oncol 2007, 1:160–171.
28. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T,
Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA: SOURCE: a unified
genomic resource of functional annotations, ontologies, and gene
expression data. Nucleic Acids Res 2003, 31:219–223.
29. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen
H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO,
Børresen-Dale AL, Botstein D: Repeated observation of breast tumor
subtypes in independent gene expression data sets. Proc Natl Acad Sci
USA 2003, 100:8418–8423.
30. Wider G, Dreier L: Measuring protein concentrations by NMR
spectroscopy. J Am Chem Soc 2006, 128:2571–2576.
31. Eilers PH: Parametric time warping. Anal Chem 2003, 76:404–411.
32. Savorani F, Tomasi G, Engelsen SB: icoshift: a versatile tool for the rapid
alignment of 1D NMR spectra. J Magn Reson 2010, 202:190–202.
33. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res 2000, 28:27–30.
34. Michel V, Yuan ZM, Ramsubir S, Bakovic M: Choline transport for
phospholipid synthesis. Exp Biol Med 2006, 231:490–504.
35. Gallazzini M, Ferraris JD, Burg MB: GDPD5 is a glycerophosphocholine
phosphodiesterase that osmotically regulates the osmoprotective
organic osmolyte GPC. Proc Natl Acad Sci USA 2008, 105:11026–11031.
36. Rosner B: Percentage points for a generalized ESD many-outlier
procedure. Technometrics 1983, 25:165–172.
37. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H,
van de Vijver MJ: Gene expression profiling and histopathological
characterization of triple-negative/basal-like breast carcinomas. Breast
Cancer Res 2007, 9:R65.
38. Sorlie T: Molecular portraits of breast cancer: tumour subtypes as distinct
disease entities. Eur J Cancer 2004, 40:2667–2675.
39. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox
SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on
gene expression profiles from a population-based study. Proc Natl Acad
Sci USA 2003, 100:10393–10398.
40. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Borresen-Dale AL,
Engebraaten O, Maelandsmo GM, Gribbestad IS: Distinct choline metabolic
profiles are associated with differences in gene expression for basal-like
and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433.
41. Galons JP, Job C, Gillies RJ: Increase of GPC levels in cultured mammalian
cells during acidosis. A 31P MR spectroscopy study using a continuous
bioreactor system. Magn Reson Med 1995, 33:422–426.
42. Mori N, Glunde K, Takagi T, Bhujwalla ZM: The tumor microenvironment
alters choline phospholipid metabolism detected by comparing cancer
cells with tumors: [abstract]. Proc Intl Soc Mag Reson Med 2008, 2008:16.
43. Contractor K, Kenny L, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C,
Shousha S, Lewis J, Hogben K, De Nguyen Q, Coombes RC, Aboagye EO:
Biological basis of [11C] choline-positron emission tomography in
patients with breast cancer: comparison with [11 F] fluorothymidine
positron emission tomography. Nucl Med Commun 2011, 32:997–1004.
44. Ebenhan T, Honer M, Ametamey SM, Schubiger PA, Becquet M, Ferretti S,
Cannet C, Rausch M, McSheehy PJ: Comparison of [18 F]-tracers in various
experimental tumor models by PET imaging and identification of an
early response biomarker for the novel microtubule stabilizer
patupilone. Mol Imaging Biol 2009, 11:308–321.45. Eliyahu G, Kreizman T, Degani H: Phosphocholine as a biomarker of breast
cancer: molecular and biochemical studies. Int J Cancer 2007, 120:1721–1730.
46. Kouji H, Inazu M, Yamada T, Tajima H, Aoki T, Matsumiya T: Molecular and
functional characterization of choline transporter in human colon
carcinoma HT-29 cells. Arch Biochem Biophys 2009, 483:90–98.
47. Ramírez de Molina A, Gutiérrez R, Ramos MA, Silva JM, Silva J, Bonilla F,
Sánchez JJ, Lacal JC: Increased choline kinase activity in human breast
carcinomas: clinical evidence for a potential novel antitumor strategy.
Oncogene 2002, 21:4317–4322.
48. Moestue SA, Giskeødegård GF, Cao MD, Bathen TF, Gribbestad IS:
Glycerophosphocholine (GPC) is a poorly understood biomarker in
breast cancer. Proc Natl Acad Sci USA 2012, 109:E2506.
49. Delikatny EJ, Chawla S, Leung DJ, Poptani H: MR-visible lipids and the
tumor microenvironment. NMR Biomed 2011, 24:592–611.
50. Milkevitch M, Beardsley NJ, Delikatny EJ: Phenylbutyrate induces apoptosis
and lipid accumulations via a peroxisome proliferator-activated receptor
gamma-dependent pathway. NMR Biomed 2010, 23:473–479.
51. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H,
Glickson JD, Delikatny EJ: Increases in NMR-visible lipid and glyceropho-
sphocholine during phenylbutyrate-induced apoptosis in human pros-
tate cancer cells. Biochim Biophys Acta 2005, 1734:1–12.
52. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C,
Gillies RJ: Response of choline metabolites to docetaxel therapy is
quantified in vivo by localized 31P MRS of human breast cancer
xenografts and in vitro by high-resolution 31P NMR spectroscopy of cell
extracts. Magn Reson Imaging 2007, 58:270–280.
53. Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE,
Bhujwalla ZM, Gribbestad IS, Glunde K: Glycerophosphodiester
phosphodiesterase domain containing 5 (GDPD5) expression correlates
with malignant choline phospholipid metabolite profiles in human
breast cancer. NMR Biomed 2012, 25:1033–1042.
54. Guthridge CJ, Stampfer MR, Clark MA, Steiner MR: Phospholipases A2 in
ras-transformed and immortalized human mammary epithelial cells.
Cancer Lett 1994, 86:11–21.
55. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett
B, Raghunand N, Gillies RJ: Characterization of breast cancers and therapy
response by MRS and quantitative gene expression profiling in the
choline pathway. NMR Biomed 2009, 22:114–127.
56. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS:
Overexpression of phospholipase D1 in human breast cancer tissues.
Cancer Lett 2000, 161:207–214.
57. Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T, Stallings JD:
Expression and function of phospholipase C in breast carcinoma. Adv
Enzyme Regul 2009, 49:59–73.
58. Farooqui AA, Horrocks LA: Signaling and interplay mediated by
phospholipases A2, C, and D in LA-N-1 cell nuclei. Reprod Nutr Dev 2005,
45:613–631.
59. Macara IG: Elevated phosphocholine concentration in ras-transformed
NIH 3 T3 cells arises from increased choline kinase activity, not from
phosphatidylcholine breakdown. Mol Cell Biol 1989, 9:325–328.
60. Ratnam S, Kent C: Early increase in choline kinase activity upon induction
of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem
Biophys 1995, 323:313–322.
61. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM: Choline kinase down-
regulation increases the effect of 5-fluorouracil in breast cancer cells.
Cancer Res 2007, 67:11284–11290.
62. Dawson SJ, Rueda OM, Aparicio S, Caldas C: A new genome-driven inte-
grated classification of breast cancer and its implications. EMBO J 2013,
32:617–628.
63. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D,
Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell
R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E,
Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham
A, Børresen-Dale AL, Brenton JD, Tavaré S, et al: The genomic and
transcriptomic architecture of 2,000 breast tumours reveals novel
subgroups. Nature 2012, 486:346–352.
doi:10.1186/bcr3597
Cite this article as: Grinde et al.: Interplay of choline metabolites and
genes in patient-derived breast cancer xenografts. Breast Cancer Research
2014 16:R5.
